Drug Profile
Research programme: RAF kinase inhibitors - Merck & Co
Alternative Names: ARQ 218; ARQ 680; ARQ-350RPLatest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule
- Class Imidazoles; Oxazoles; Piperidines; Pyrazoles; Pyrimidines
- Mechanism of Action Mitogen-activated protein kinase inhibitors; Proto oncogene protein b raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 31 May 2006 This programme is still in active development